Articles from Artera

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced the launch of its DIRECT-AI registry study. This study will assess how the ArteraAI Prostate Test influences treatment decision-making between clinicians and patients with localized prostate cancer. Additionally, the study will monitor participants to evaluate their long-term cancer outcomes, reinforcing Artera's commitment to advancing personalized cancer treatment and identifying future opportunities for test optimization.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today it has received its New York laboratory permit from its Department of Health. This licensure allows Artera to offer the award-winning ArteraAI Prostate Test to one of the largest healthcare markets and makes the test available to all patients across the United States.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated its award-winning ArteraAI Prostate Test with new insights to help higher-risk patients optimize treatment decisions. Artera recently presented its validation data at the 2025 ASCO Annual Meeting, demonstrating the test’s ability to identify high-risk, non-metastatic prostate cancer patients most likely to benefit from the addition of abiraterone to standard therapy from those who don’t.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the presentation of two new abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including an oral presentation selected for Best of ASCO 2025, an honor reserved for studies with the greatest potential to shape the future of cancer care.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced the publication of a validation study in the JCO Clinical Cancer Informatics on Artera’s MMAI model. The study assessed the ability of the MMAI model to perform similarly across racial subgroups using data from prostate cancer trials with diverse representation.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the first patient enrollment in PROSTATE-IQ, a Phase 3 clinical trial in men with prostate cancer recurrence after prostatectomy. The trial utilizes the ArteraAI Prostate Test to enable treatment personalization by determining cancer metastasis risk and identifying whether patients may be able to reduce or avoid hormone therapy.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, announced today that they will collaborate to expand access to the ArteraAI Prostate Test. Through the collaboration, Tempus and Artera will work together in an exclusive manner to commercialize Artera’s prostate cancer risk stratification test. Tempus is currently connected to more than 50% of all oncologists practicing in the United States.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced that its MMAI platform has been named among TIME’s Best Inventions of 2024 in the medical care category. Each year, TIME honors 200 groundbreaking inventions that are making the world a better place. Submissions from around the globe are rigorously evaluated, with winners selected based on originality, efficacy, ambition, and impact.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today it has received its California laboratory license from the California Department of Public Health (CDPH). This licensure allows Artera to offer its innovative ArteraAI Prostate Test to one of the largest healthcare markets in the United States.

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present two oral abstracts at the 2024 American Society for Radiation Oncology Annual Meeting (ASTRO).

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today an update to the ArteraAI Prostate Test, enabling clinicians to make more informed decisions about active surveillance when delivering care to prostate cancer patients.

Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, will present three abstracts at the 2024 ASCO Annual Meeting demonstrating that its multimodal artificial intelligence (MMAI) platform provides significant prognostic value across various stages of prostate cancer and for early stage breast cancer. These studies build upon the first AI-enabled test that delivers prognostic and predictive insights for localized prostate cancer patients: ArteraAI Prostate Test.

Artera, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, launches publicly today with $90M in funding. The investment comes from a syndicate of prominent tech and healthcare investors, comprised of seven institutions (Coatue, Johnson & Johnson Innovation – JJDC, Inc., Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, The Factory) and 11 angel investors (Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, Michael Driscoll).

Artera, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced new data today at ASCO GU 2023 demonstrating that its multimodal artificial intelligence (MMAI) prognostic biomarker can help bring more personalized treatment to men with localized prostate cancer.